History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward

Cephalalgia

Volumn 28, Issue 8, 2008, Pages 877-886

  Tfelt Hansen, P C ^a,c   Koehler, P J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sittard Geleen Heerlen   (Netherlands)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Dihydro Ergotamine; Ergotamine; Ergotamine overuse headache; Ergotism; Migraine; Migraine pathophysiology

Indexed keywords

ADRENALIN; CAFFEINE; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOT ALKALOID; ERGOTAMINE; ERGOTAMINE TARTRATE; GLYCERYL TRINITRATE; HEPARIN; METHYSERGIDE; PLACEBO; PROTEINASE INHIBITOR; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; VASOCONSTRICTOR AGENT;

ANALGESIA; ARTICLE; BLOOD PRESSURE; BRAIN ARTERY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; ERGOTISM; HEADACHE; HUMAN; INHIBITION KINETICS; INTERMITTENT CLAUDICATION; MIGRAINE; NONHUMAN; ORTHOSTATIC HYPERTENSION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPATHETIC TONE; TEMPORAL CORTEX; THROMBOPHLEBITIS; TREATMENT OUTCOME; UNITED STATES; UTERUS CONTRACTION; VASOCONSTRICTION; VASODILATATION; HISTORY; INTERNATIONAL COOPERATION;

CLINICAL TRIALS AS TOPIC; ERGOTAMINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONALITY; MIGRAINE DISORDERS; VASOCONSTRICTOR AGENTS;

EID: 51649087231     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01578.x     Document Type: Article

References (109)

1. Isler H. Thomas Willis' chapters on headache of 1672. Headache 1986; 26:95-8.
2. Isler H. History of the headache. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins 2006:1-7.
3. Wolff HG. Headache and other head pain, 2nd edn. New York: Oxford University Press 1963.
4. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969; 2:1-28.
5. Liveing E. On megrim, sick headache, and some allied disorder. A contribution to the pathology of nerve storm. London: J. & A. Churchill 1873.
6. Gowers W. A Manual of disease of the nervous system. London: Churchill 1886-1888.
7. Blau JN. Migraine pathogenesis: the neural hypothesis re-examined. J Neurol Neurosurg Psychiatry 1984; 47:437-42.
8. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002; 346:257-70.
9. Saxena PR. The effects of antimigraine drugs on the vascular responses by-5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimi- graine action. Headache 1972; 12:44-54.
10. Saxena PR, De Vlaam-Schluter GM. Role of some bio- genic substances in migraine and relevant mechanism in antimigraine action of ergotamine-studies in an experimental model for migraine. Eur J Pharmacol 1974; 27:99-105.
11. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988; 8:83-91.
12. Hoskin KL, Kaube H, Goadsby PG. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996; 119:249-56.
13. Woakes E. On ergot rye in the treatment of neuralgia. BMJ 1868; II:360-1.
14. Koehler PJ, Isler H. The early use of ergotamine in migraine, Edward Woakes' report of 1868, its theoretical and practical background and international reception. Cephalalgia 2002; 22:686-91.
15. Koehler PJ. Brown-Sequard's comment on Du Bois Rey- mond's 'He mik rania sympathicotonia'. Cephalalgia 1995; 15:370-2.
16. Dale HH. On some physiological actions of ergot. J Physiol (Lond) 1906; 34:163-206.
17. Berde B, Schild HO, eds. Ergot alkaloids and related compounds. Handbook of experimental pharmacology, Vol. 49. Berlin: Springer-Verlag 1978:1-1001.
18. Ahlquist RP. A study of the adrenotopic receptors. Am J Physiol 1948; 153:586-600.
19. Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verh Schweiz Naturf Ges 1918; 101:190-1.
20. Rothlin E. Historical development of the ergot therapy of migraine. Int Arch Allergy 1955; 7:205-9.
21. Hofmann A. Historical view of ergot alkaloids. Pharmacology 1978; 16 (Suppl. 1):1-11.
22. Rothlin E. Contribution a la methode chimique d'exploration du systeme sympathique. Rev Neurol 1926; 33:1108-13.
23. Maier HW. L'ergotamine inhibitteur du sympathique etudie en clinique, comme moyen d'exploration et comme agent therapeutique. Rev Neurol 1926; 33: 1104-8.
24. Trautmann E. Die Beeinflussung migraneartiger Zustande durch ein sympathikushemmendes Mittel (Gynergen). Munch med Wochenschr 1928; 75:513.
25. Tzanck MA. Le traitement des migraines par le tartrate d'ergotamine. Bull Soc Med Paris 1928; 44:1057.
26. Brock S, O'Sullivan M, Young D. the effect of non- sedative drugs and other measures in migraine, with special reference to ergotamine tartrate. Am J Med Sci 1934; 188:253-60.
27. Lennox WG. The use of ergotamine tartrate in migraine. N Engl J Med 1934; 210:1061-5.
28. Logan AH, Allen EV. The treatment of migraine with ergotamine tartrate. Proc Mayo Clin 1934; 9:585-58.
29. Lennox WG, von Storch TJC. Experience with ergota- mine tartrate in 120 patients with migraine. JAMA 1935; 105:169-71.
30. O'Sullivan ME. Termination of one thousand attacks of migraine with ergotamine tartrate. JAMA 1936; 107: 1208-12.
31. Lennox WG. Ergonovine versus ergotamine as a termi0nator of migraine headaches. Am J Med Sci 1938; 195:458-68.
32. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39:737-63.
33. Brazil P, Friedman AP. Further observations in cranio- vascular studies. Neurology 1957; 7:52-5.
34. Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 1986; 59 (Suppl. 3):1-30.
35. Silberstein SD, McCrory DC. Ergotamine and dihydro- ergotamine: history, pharmacology, and efficacy. Headache 2003; 43:144-66.
36. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc 1945; 20:241-8.
37. Friedman MD, Friedman DA. Dihydroergotamine (DHE-45) in the treatment of migraine: preliminary clinical observations. Ohio Med J 1945; 41:1009-100.
38. Hartman MM. Parenteral use of dihydroergotamine. Ann Allergy 1945; :440-2.
39. Spühler O. Dihydroergotamine (DHE) als Sympatholyti- cum in der inneren Medizin. Schweiz med Wschr 1946; 76:1259-63.
40. Chapuies JP. Migraines, céphalées et sympathicolyp-tiques. Schweiz med Wschr 1948; 78:1125-6.
41. Kral UA. Neurologische Erfahrungen mit 'Dihydroer- gotamine'. Scweiz med Wschr 1948; 62:128-50.
42. Evers S, Mylecharane EJ. Nonsteriodal anti- inflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Goadsby P, Ramadan N, Tfelt- Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins 2006:553-66.
43. Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke 1987; 18:120-3.
44. de Hoon JNJM, Poppe KA, Thijsen HHW, Struijker- Boudier HAJ, Van Bortel LMAB. Dihydroergotamine: discrepancy between arterial, arteriolar and pharmaco-kinetic data. Br J Clin Pharmacol 2001; 52:45-51.
45. Aellig WH, Rosenthaler J. Venoconstrictor effect of dihy-droergotamine (DHE) after intranasal and i.m. administration. Eur J Clin Pharmacol 1986; 30:581-4.
46. Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffman A, Schmidt A, Beck H. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Haemost 1996; 75:246-50.
47. Fouad FM, Tarazi RC, Bravo EL. Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy. Clin Pharmacol 1981 191:782-9.
48. Raskin NH. Treatment of status migrainosus: the American experience. Headache 1990; 30 (Suppl. 2):550-3.
49. Scott AK. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neu-ropharmacol 1992; 15:289-96.
50. Saper JR, Silberstein S. Pharmacology of dihydroergota- mine and evidence for efficacy and safety in migraine. Headache 2006; 46 (Suppl. 4):S171-S181.
51. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins 2006:459-67.
52. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins 2006:469-502.
53. Dahlof C. Placebo-controlled clinical trials with ergota- mine in the acute treatment of migraine. Cephalalgia 1993; 13:166-71.
54. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P et al. Ergotamine in the acute treatment of migraine-European Consensus. Brain 2000; 123:9-18.
55. Dahlof C. Clinical efficacy and tolerability of sumatrip- tan tablets and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia 2001; 21 (Suppl. 1):9-12.
56. Galer BS, Lipton RB, Solomon S, Newman LC, Spierings ELH. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache 1991; 31: 446-50.
57. Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In: de Wolf FA, ed. Handbook of clinical neurology, Vol. 21 (65): intoxications of the nervous system. Part II. Amsterdam: Elsevier Science B.V. 1995:61-78.
58. Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine used for migraine. Headache 1963; 3:214-26.
59. Rowsel AR, Neylan C, Wilkinson M. Ergotamine induced headaches in migrainous patients. Headache 1973; 13:65-7.
60. Andersson PG. Ergotamine headache. Headache 1975; 15:118-21.
61. Tfelt-Hansen P, Krabbe AA. Ergotamine abuse. Do patients benefit from withdrawal? Cephalalgia 1981; 1:29-32.
62. Ala-Hurula V, Myllylä VV, Hokkanen E. Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentration. Cephala-lgia 1982; 2:189-95.
63. Saper J, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986; 9:244-56.
64. Saper JR. Ergotamine dependency-a review. Headache 1987; 27:435-8.
65. Diener HC, Silberstein S. Medication overuse headache. In: Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins 2006:971-9.
66. Harrison TE. Ergotaminism. J Am Coll Emerg Physicians 1978; 7:162-9.
67. Rothlin E, Cerletti A. Untersuchung iiber die Kreislauf- wirkung des Ergotamins. Helv Physiol Pharmacol Acta 1949; 7:333-70.
68. Silverskiold BP. Gynergen abuse in cases of migraine. Acta Psychiatrica Scand 1947; Suppl. 46:281-5.
69. Peters GA, Horton BT. Headache with special reference to the excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951; 26:153-61.
70. Boes CJ, Capobianco DJ. Chronic migraine and medication-overuse headache through the ages. Ceph-alalgia 2005; 25:378-90.
71. Capobianco DJ, Swanson JW, Dodick DW. Medication- induced (analgesic rebound) headache: historical aspects and initial descriptions of he North American experience. Headache 2001; 41:500-2.
72. Lippman CW. Characteristic headache resulting from prolonged use of ergot derivatives. J Nerv Ment Dis 1955; 121:270-3.
73. Friedmanm AP, Brazil P, von Storch TJC. Ergotamine tolerance in patients with migraine. JAMA 1955; 157:881-4.
74. Yater WM, Cahill JA. Bilateral gangrene of feet due to ergotamine tartrate used for pruritis or jaundice. JAMA 1936; 106:1625-31.
75. Ludolph AC, Husstedt IW, Schalke HP, Grotemeyer KH, Brune GG. Chronic ergotamine abuse: evidence for
76. functional impairment of long ascending spinal tracts. Eur Neurol 1988; 28:311-16.
77. Lamb D, Persaud N, Volans G. Acute ergotamine poisoning. Hum Toxicol 1983; 2:424.
78. Barger G. Ergot and ergotism. Edinburgh: Gurney & Jackson 1931.
79. Fanciulatti M, Allessandri M, Pitrini U, Briccolani- Bandini E, Beatrice S. Long-term ergotamine abuse: effect on adrenergically induced mydriasis. Clin Pharmacol Ther 1992; 51:302-7.
80. Tfelt-Hansen P, 0stergaard JR, Gothgen I, Jacobsen E, Rasmussen JP, Husum B. Nitroglycerin for ergotism- experimental studies in vitro and in migraine patients and treatment of an overt case. Eur J Clin Pharmacol 1982; 22:105-9.
81. D'Amore MJ, Borge MA, Messersmith RN. Limb- threatening lower extremity ischemia successfully treated with intra-arterial infusion-case reports. Angi- ology 1999; 50:233-7.
82. Silberstein SD, Young WB. Safety and efficacy of ergota- mine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995; 45:577-84.
83. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for migraine. Am J Med Sci 1967; 254:1-12.
84. Hendrikx M, van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996; 5:235-7.
85. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Post grad Med J 1999; 75:546-7.
86. Rosenthal E, Sala F, Chichmanian RM, Batt M, Casuto JP. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA 1999; 281: 987.
87. Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergota- mine. Am J Med 2001; 110:594.
88. Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. Headache 2002; 42:694-5.
89. Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology 2001; 57:743-4.
90. Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 2003; 37:676-8.
91. Dige-Petersen H, Lassen NA, Noer I, Tennesen KH, Olesen J. Subclinical ergotism. Lancet 1977; 2:65-6.
92. Tfelt-Hansen P, Olesen J. Arterial response to ergota- mine tartrate in abusing and non-abusing migraine patients. Acta Pharmacol Toxicol 1981; 48:69-72.
93. Tfelt-Hansen P, Kanstrup I-L, Christensen NJ, Winkler K. General and regional haemodynamic effects of intravenous ergotamine in man. Clin Sci 1983; 65:599-604.
94. Aellig WH, Nuesch E. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after
95. oral and intravenous administration in man. Int J Clin Pharmacol 1977; 15:106-12.
96. Edlund P-O. Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection. J Chromatogr 1981; 226:107-15.
97. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavail- ability of ergotamine tartrate after oral and rectal administration in migraine suffers. Br J Clin Pharmacol 1983; 16:695-9.
98. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharma- cokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986; 30:331-4.
99. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 1984; 26:4463-70.
100. Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arterio-venous shunting of radioactive microspheres in the head. Br J Pharmacol 1978; 63:541-9.
101. De Vries P, Villalon CM, Heiligers JPC, Saxena PR. Characterisation of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br J Pharmacol 1998; 123:1561-70.
102. Saxena PR. Selective carotid vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine action. Eur J Pharmacol 1974; 27:99-105.
103. Saxena PR, Verdouw PD. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 1984; 82:817-26.
104. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti- migraine drug sumatriptan. Eur Neurol 1991; 31:282-90.
105. Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache 2007; 47 (Suppl. 1):S10-S19.
106. Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK et al. Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia 1989; 9 (Suppl. 9):73-7.
107. Winner P, Ricalde O, Le Force B, Saper J, Margul B. Adouble-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53:180-4.
108. Tfelt-Hansen P, Nilsson E, Edvinsson L. Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. J Headache Pain 2007; 8:83-9.
109. Gaist D. Use and overuse of sumatriptan. Pharmacoepi- demiological studies based on prescription register and interview data. Cephalalgia 1999; 19:735-61.